[go: up one dir, main page]

MX2016007803A - Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. - Google Patents

Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.

Info

Publication number
MX2016007803A
MX2016007803A MX2016007803A MX2016007803A MX2016007803A MX 2016007803 A MX2016007803 A MX 2016007803A MX 2016007803 A MX2016007803 A MX 2016007803A MX 2016007803 A MX2016007803 A MX 2016007803A MX 2016007803 A MX2016007803 A MX 2016007803A
Authority
MX
Mexico
Prior art keywords
nervous system
omega
compositions
fatty acids
treat diseases
Prior art date
Application number
MX2016007803A
Other languages
English (en)
Other versions
MX390909B (es
Inventor
Georgiou Tassos
Original Assignee
Georgiou Tassos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiou Tassos filed Critical Georgiou Tassos
Publication of MX2016007803A publication Critical patent/MX2016007803A/es
Publication of MX390909B publication Critical patent/MX390909B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/08—Food product presented as a kit of parts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1868—Docosahexaenoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/187—Eicosapentaenoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composiciones que comprenden ácidos grasos omega 3 para usar en el tratamiento, la mejoría o la prevención de diversos trastornos, afecciones y enfermedades que implican daños al sistema nervioso, como la neuropatía periférica del sistema nervioso y el glaucoma.
MX2016007803A 2013-12-19 2013-12-19 Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. MX390909B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/077356 WO2015090394A1 (en) 2013-12-19 2013-12-19 Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

Publications (2)

Publication Number Publication Date
MX2016007803A true MX2016007803A (es) 2017-08-10
MX390909B MX390909B (es) 2025-03-21

Family

ID=50137601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007803A MX390909B (es) 2013-12-19 2013-12-19 Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.

Country Status (24)

Country Link
US (2) US20160331712A1 (es)
EP (1) EP3082795B1 (es)
JP (1) JP6389893B2 (es)
KR (1) KR101898358B1 (es)
CN (1) CN105828813A (es)
AU (1) AU2013407946B2 (es)
BR (1) BR112016014182A2 (es)
CA (1) CA2934600C (es)
CY (1) CY1123942T1 (es)
DK (1) DK3082795T3 (es)
ES (1) ES2813383T3 (es)
HR (1) HRP20201221T1 (es)
HU (1) HUE050205T2 (es)
IL (1) IL246254B (es)
LT (1) LT3082795T (es)
MX (1) MX390909B (es)
MY (1) MY185412A (es)
PH (1) PH12016501159B1 (es)
PL (1) PL3082795T3 (es)
PT (1) PT3082795T (es)
RS (1) RS60862B1 (es)
RU (1) RU2667640C1 (es)
UA (1) UA117274C2 (es)
WO (1) WO2015090394A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
KR20220143685A (ko) 2020-02-06 2022-10-25 퍼퓨즈 세라퓨틱스, 인크. 안질환의 치료를 위한 조성물
EP4288046A4 (en) * 2021-02-08 2024-12-11 Synaptogenix, Inc. TREATMENT OF OPTIC NERVE INFECTION WITH PKC ACTIVATORS
AU2022264036A1 (en) 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
CA2598525A1 (en) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. Nerve regeneration promoting agent
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
US20090182022A1 (en) * 2006-01-05 2009-07-16 Reliant Pharmaceuticals Treatment of Fatty Liver
EP1900378A1 (en) 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
PT2429317T (pt) * 2009-04-17 2016-07-22 Natac Pharma S L Composições ricas em ácidos gordos ómega-3 com um teor baixo de ácido fitânico
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
JP2014504605A (ja) * 2011-01-25 2014-02-24 ネステク ソシエテ アノニム 動物の視覚系の劣化を治療、緩和又は予防するための方法及び組成物
RU2013142437A (ru) * 2011-02-18 2015-03-27 Нестек С.А. Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US9314445B2 (en) * 2011-09-12 2016-04-19 Tassos Georgiou Use of omega fatty acids for treating disease

Also Published As

Publication number Publication date
RU2667640C1 (ru) 2018-09-21
KR101898358B1 (ko) 2018-09-12
CY1123942T1 (el) 2022-03-24
DK3082795T3 (da) 2020-08-24
RU2016129079A (ru) 2018-01-24
AU2013407946A1 (en) 2016-08-04
PT3082795T (pt) 2020-08-27
ES2813383T3 (es) 2021-03-23
EP3082795B1 (en) 2020-05-20
US20160331712A1 (en) 2016-11-17
AU2013407946B2 (en) 2017-09-07
MY185412A (en) 2021-05-18
PH12016501159B1 (en) 2022-11-23
JP2017501169A (ja) 2017-01-12
HRP20201221T1 (hr) 2020-11-13
CA2934600C (en) 2018-11-20
KR20160093729A (ko) 2016-08-08
CA2934600A1 (en) 2015-06-25
AU2013407946A2 (en) 2016-08-25
PL3082795T3 (pl) 2020-11-16
MX390909B (es) 2025-03-21
HUE050205T2 (hu) 2020-11-30
IL246254B (en) 2021-04-29
BR112016014182A2 (pt) 2017-08-08
PH12016501159A1 (en) 2016-08-15
JP6389893B2 (ja) 2018-09-12
UA117274C2 (uk) 2018-07-10
EP3082795A1 (en) 2016-10-26
CN105828813A (zh) 2016-08-03
US20190192466A1 (en) 2019-06-27
US10905671B2 (en) 2021-02-02
RS60862B1 (sr) 2020-11-30
LT3082795T (lt) 2020-11-10
WO2015090394A1 (en) 2015-06-25
IL246254A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX389449B (es) Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX2017004998A (es) Composicion que contiene un extracto o fraccion de una planta del genero justicia.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112016025396A2 (pt) derivados de heterociclil-butanamida
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2017005064A (es) Metodos para tratar afecciones oculares.
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.